Published in Cell on July 20, 2012
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med (2013) 4.26
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (2015) 3.29
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Mutational status of naevus-associated melanomas. Br J Dermatol (2015) 2.68
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
The landscape of kinase fusions in cancer. Nat Commun (2014) 2.48
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
POT1 loss-of-function variants predispose to familial melanoma. Nat Genet (2014) 2.40
ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell (2013) 2.32
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst (2014) 2.29
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov (2014) 2.09
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell (2015) 1.91
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature (2014) 1.85
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood (2014) 1.81
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res (2014) 1.70
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods (2013) 1.64
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell (2013) 1.60
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58
RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet (2014) 1.57
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet (2015) 1.57
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. Genome Biol (2013) 1.54
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol (2013) 1.53
UV signature mutations. Photochem Photobiol (2014) 1.52
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50
Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res (2014) 1.47
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2015) 1.47
Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Mol Cell (2015) 1.47
Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models. Genome Biol (2015) 1.46
Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene (2013) 1.44
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res (2013) 1.43
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One (2016) 1.41
Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation. PLoS One (2013) 1.41
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41
Whole-genome landscapes of major melanoma subtypes. Nature (2017) 1.40
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol (2013) 1.38
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
UV radiation and the skin. Int J Mol Sci (2013) 1.37
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res (2013) 1.34
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33
Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol (2014) 1.28
PAK signaling in cancer. Cell Logist (2012) 1.27
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene (2014) 1.24
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
G quadruplexes are genomewide targets of transcriptional helicases XPB and XPD. Nat Chem Biol (2014) 1.22
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther (2014) 1.21
The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21
VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data. PLoS Comput Biol (2014) 1.20
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell (2014) 1.20
A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet (2015) 1.15
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer (2014) 1.14
Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins. Proc Natl Acad Sci U S A (2013) 1.13
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics (2005) 34.83
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol (2005) 16.77
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 16.30
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Localized Rac activation dynamics visualized in living cells. Science (2000) 7.00
Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet (2011) 6.52
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics (2006) 5.56
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature (2006) 2.87
Rho GTPase function in tumorigenesis. Biochim Biophys Acta (2009) 2.81
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2011) 2.36
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2. J Cell Biol (2010) 1.73
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
Phox homology band 4.1/ezrin/radixin/moesin-like proteins function as molecular scaffolds that interact with cargo receptors and Ras GTPases. Proc Natl Acad Sci U S A (2011) 1.57
Protein phosphatase 6 regulatory subunits composed of ankyrin repeat domains. Biochemistry (2008) 1.42
How sunlight causes melanoma. Curr Oncol Rep (2010) 1.34
TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene (2003) 1.33
Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle (2007) 1.27
Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. Cancer Res (2005) 1.10
Aurora B -TACC1 protein complex in cytokinesis. Oncogene (2004) 1.07
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
The generic genome browser: a building block for a model organism system database. Genome Res (2002) 42.64
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet (2008) 19.55
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol (2010) 18.44
The mammalian epigenome. Cell (2007) 18.13
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89